Xoma's design changes for sepsis trial

The start of a third Phase III sepsis trial by Xoma Corp. and Pfizer Inc. puts them back at the head of the sepsis queue.

A year ago, XOMA appeared to have fallen into last place in the sepsis race when the FDA said it wasn't prepared to approve XOMA's E5 monoclonal antibody based on the data submitted. But since then, Centocor Inc. has had to suspend its second Phase III trial and hasn't begun a new one, while Synergen Inc. also will have to do another Phase III study. ...